<span item_type="fundamental" item_id="4a96f221eb45324c8d6d7608888ba12d" counter_id="ST/US/CLOV" env="prod"></span><span item_type="announcement" item_id="580139431129779841" env="prod"></span><p>Revenue: As of FY2025 Q3, the actual value is USD 496.65 B, beating the estimate of USD 471.08 M.</p><p>EPS: As of FY2025 Q3, the actual value is USD -0.05.</p><p>EBIT: As of FY2025 Q3, the actual value is USD -29.65 B, missing the estimate of USD -18.33 M.</p><p></p><h3>Insurance Segment</h3><h4>Premiums Earned, Net</h4><ul><li>For the three months ended September 30, 2025, premiums earned, net were $479.1 million, a 48.5% increase from $322.6 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li><li>For the nine months ended September 30, 2025, premiums earned, net were $1,405.9 million, a 38.6% increase from $1,014.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>Net Medical Claims Incurred</h4><ul><li>For the three months ended September 30, 2025, net medical claims incurred were $423.5 million, a 69.5% increase from $249.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li><li>For the nine months ended September 30, 2025, net medical claims incurred were $1,154.9 million, a 51.3% increase from $763.3 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>Salaries and Benefits</h4><ul><li>For the three months ended September 30, 2025, salaries and benefits were $48.2 million, a 12.4% decrease from $55.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li><li>For the nine months ended September 30, 2025, salaries and benefits were $168.5 million, a 0.7% decrease from $169.7 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>General and Administrative Expenses</h4><ul><li>For the three months ended September 30, 2025, general and administrative expenses were $49.0 million, a 39.1% increase from $35.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li><li>For the nine months ended September 30, 2025, general and administrative expenses were $148.1 million, a 19.3% increase from $124.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>Net Loss from Continuing Operations</h4><ul><li>For the three months ended September 30, 2025, the net loss from continuing operations was $24.4 million, compared to a net loss of $8.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li><li>For the nine months ended September 30, 2025, the net loss from continuing operations was $36.2 million, compared to a net loss of $24.8 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h3>Cash Flow</h3><h4>Operating Cash Flow</h4><ul><li>Net cash provided by operating activities from continuing operations was $1.2 million for the nine months ended September 30, 2025, compared to $129.5 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>Investing Cash Flow</h4><ul><li>Net cash provided by investing activities was $39.1 million for the nine months ended September 30, 2025, compared to $2.0 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>Financing Cash Flow</h4><ul><li>Net cash used in financing activities was $44.8 million for the nine months ended September 30, 2025, compared to $11.2 million for the same period in 2024.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h3>Future Outlook and Strategy</h3><h4>Core Business Focus</h4><ul><li>Clover Health aims to empower physicians with technology to identify, manage, and treat chronic diseases earlier, focusing on improving care for Medicare beneficiaries through its Clover Assistant platform.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul><h4>Non-Core Business</h4><ul><li>The company launched Counterpart Health, Inc., a SaaS and Tech Enabled Services Solution, to extend the benefits of its technology to a wider audience, aiming for growth and high-margin business opportunities.<span class="superscript" item_id="0" item_type="announcement_file" value="1" url="https://www.sec.gov/Archives/edgar/data/1801170/000180117025000275/clov-20250930.htm"></span></li></ul>

Clover Health Investments | 10-Q: FY2025 Q3 Revenue Beats Estimate at USD 496.65 B